Abstract: Early-stage lung cancer diagnosis is often hindered by low contrast, subtle tumour morphology, and incomplete feature representation across imaging modalities. To overcome these limitations, ...
Abstract: The Lung cancer remains to abundant as a leading reason of cancer-associated death worldwide, which necessitates early recognition for increasing survival rates. Standard diagnostic ...
Talk about being a dedicated paw-rent. When his 8-year-old dog Rosie had mere months to live due to deadly mast cell cancerous tumors, Australian tech entrepreneur Paul Conyngham took matters into his ...
LMH Health, 325 Maine St., is pictured in May 2021. “The biopsy came back positive. It’s lung cancer.” Countless people in our community hear these words no one ever expects. Lung cancer is one of the ...
Orders for CyPath® Lung by physicians and clinics rose 67% YoY due to peer-to-peer marketing, positive real-world experiences and growing test awareness SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity ...
Australia's Therapeutic Goods Administration has recently granted approval for an AI-powered lung cancer detection platform developed by the United Kingdom-based Optellum. The Virtual Nodule Clinic ...
A multicancer early detection (MCED) test was developed and validated in the case-control Circulating Cell-free Genome Atlas (CCGA) study (ClinicalTrials.gov identifier: NCT02889978). Previous ...
bioAffinity Technologies (NASDAQ:BIAF) announced on March 10, 2026, the launch of a large longitudinal clinical study involving 2,000 patients to evaluate the performance of its CyPath® Lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results